Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]

An Editorial – What Has Caused the Recent Review of Provenge by the CMS

There has been a lot of questions raised about why the Centers for Medicaid and Medicare Services (CMS) has out of the clear blue, launched a review of Provenge, a review that could ultimately make Provenge unavailable to men on Medicare and Medicaid (see the post:Medicare Funding for Provenge, We Urgently Need Your HELP). There [...]

Early Retiree Reinsurance Program – Helping the Younger Advanced Prostate Cancer Survivor

Those of us advanced prostate cancer survivors who are younger than 65 years and who live in the United States often face a major dilemma if we are unable to continue to work. Medicare will not provide us with medical insurance until we reach that magic age of 65 years. We can apply for social [...]

Changing the Best Practices for End of Life

It is true; life does come to an end. Dying and of course birth are the commonality we all will experience. Since we have already been born and since you are reading this you have not yet died. Therefore, it is in all of our best interests to find a way to insure that all [...]

An Interesting Look at the Health Care Insurance Industry

My post of July 9, 2009, "Will Provenge or Any Treatment for Advanced Prostate Cancer Survive Health Reform?" has caused my mailbox to become full of a number of emails both damming my concern about health care reform and supporting the concern. The negative responses have ranged from calling me selfish to being a tool [...]

Go to Top